Policy and Medicine

@CMichaelGibson The whole idea sounds really really bad. Frankenstein for microbes.

Experts warn that mirror bacteria, constructed from mirror images of molecules found in nature (R isomers instead of L isomers) could put humans, animals and plants at risk of lethal infections. Nobel laureates call for a halt to the work. Do you? theguardian.com/science/2024/d…

@CMichaelGibson Games up for CRP. Now in same class as raising HDL.

Latest on the inflammation hypothesis? CLEAR SYNERGY trial showed colchicine no different than placebo with regards to death/MI/stroke/ischemia driven revasc, despite reduction in CRP with colchicine. Dr. Jolly shares CLEAR SYNERGY results #TCT2024 clinicaltrialresults.org/wp-content/upl…

@MartyMakary Great book look for our article later this week.

What ignited the modern-day peanut allergy epidemic? An excerpt of my new book published in this week's The Harvard Gazette. Thank you everyone for your interest in the book (geni.us/blindspots). 3 wks on the New York Times bestseller list & counting! news.harvard.edu/gazette/story/…

@CMichaelGibson All the brands in the warning are white label brands, most likely came from same manufacturing facility.

FDA warns consumers not to use more than two dozen varieties of over-the-counter eyedrops because of the risk of infections that could lead to blindness. Advisory applies to lubricating drops sold by six companies, including CVS Health, Target, Rite Aid and Cardinal Health. Consumers should stop using the products immediately and avoid purchasing any that remain on pharmacy and store shelves apnews.com/article/eyedro…

The OMB concluded their review of FDA DTC advertising rule on 10/26, Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, Neutral Manner in Advertisements in Television and Radio Format: look for it 10/31 or 11/01

New post: Bipartisan Senators Ask for Additional Guidance on Transparency in Coverage Rule Recently, a bipartisan duo of policymed.com/?p=16093

New post: Congress Seeking Answers on Hospital Price Transparency Rule Compliance Recently, members of the Unite policymed.com/?p=16091

New post: CMS Fines Hospital for Noncompliance with Hospital Price Transparency Rule Recently, the Centers for Medi policymed.com/?p=16085

New post: House Subcommittee Focuses on Antimicrobial Resistance On April 28, 2023, the United policymed.com/?p=16083

New post: SouthEast Eye Specialists to Pay $17 Million to Resolve Anti-Kickback and False Claims Act Allegations It was recently announced that policymed.com/?p=16081

New post: FDA to Require Mail-Back Envelopes for Opioids Dispensed in Outpatient Settings Recently, the United States Fo policymed.com/?p=16078

New post: CCO MATE ACT DEA Resource Center Includes, Courses, Frequently Asked Questions (FAQ’s) and Additional Resources In December 2022, congress pas policymed.com/?p=16125

New post: OPDP: No More Untitled Letters? Today marks one year since the policymed.com/?p=16098

New post: PhRMA Releases Report on Global Prescription Drug Access The Pharmaceutical Research an policymed.com/?p=16035

New post: The Impact of COVID-19 Years on the ACO REACH Model The impact of the COVID-19 pan policymed.com/?p=16057

New post: PhRMA Focuses on Other Important Health Care System Improvements The Pharmaceutical Research an policymed.com/?p=16054

New post: Pioneer Institute Issues White Paper on Impact of PBMs and Copay Accumulator Programs The Pioneer Institute recently policymed.com/?p=16052

New post: AMA Survey Finds that Prior Authorization Harms Patient Care A recent physician survey foun policymed.com/?p=16050

New post: HHS OIG Releases Telehealth HHS OIG Toolkit HHS OIG has said that during 2 policymed.com/?p=16048

New post: CMS Outlines Medicare Drug Price Negotiation Program for 2026 On March 15, 2023, CMS release policymed.com/?p=16045